LIVIVO - Search results -

Search results

Result 1 - 10 of total 6039

Search options

Article ; Online: Observation of the decay B(c)(+) → B(s)(0)π+.

Aaij, R / Adeva, B / Adinolfi, M / Adrover, C / Affolder, A / Ajaltouni, Z / Albrecht, J / Alessio, F / Alexander, M / Ali, S / Alkhazov, G / Alvarez Cartelle, P / Alves, A A / Amato, S / Amerio, S / Amhis, Y / Anderlini, L / Anderson, J / Andreassen, R /

Andrews, J E / Appleby, R B / Aquines Gutierrez, O / Archilli, F / Artamonov, A / Artuso, M / Aslanides, E / Auriemma, G / Baalouch, M / Bachmann, S / Back, J J / Baesso, C / Balagura, V / Baldini, W / Barlow, R J / Barschel, C / Barsuk, S / Barter, W / Bauer, Th / Bay, A / Beddow, J / Bedeschi, F / Bediaga, I / Belogurov, S / Belous, K / Belyaev, I / Ben-Haim, E / Bencivenni, G / Benson, S / Benton, J / Berezhnoy, A / Bernet, R / Bettler, M-O / van Beuzekom, M / Bien, A / Bifani, S / Bird, T / Bizzeti, A / Bjørnstad, P M / Blake, T / Blanc, F / Blouw, J / Blusk, S / Bocci, V / Bondar, A / Bondar, N / Bonivento, W / Borghi, S / Borgia, A / Bowcock, T J V / Bowen, E / Bozzi, C / Brambach, T / van den Brand, J / Bressieux, J / Brett, D / Britsch, M / Britton, T / Brook, N H / Brown, H / Bursche, A / Busetto, G / Buytaert, J / Cadeddu, S / Callot, O / Calvi, M / Calvo Gomez, M / Camboni, A / Campana, P / Campora Perez, D / Carbone, A / Carboni, G / Cardinale, R / Cardini, A / Carranza-Mejia, H / Carson, L / Carvalho Akiba, K / Casse, G / Cassina, L / Castillo Garcia, L / Cattaneo, M / Cauet, Ch / Cenci, R / Charles, M / Charpentier, Ph / Chen, P / Cheung, S-F / Chiapolini, N / Chrzaszcz, M / Ciba, K / Cid Vidal, X / Ciezarek, G / Clarke, P E L / Clemencic, M / Cliff, H V / Closier, J / Coca, C / Coco, V / Cogan, J / Cogneras, E / Collins, P / Comerma-Montells, A / Contu, A / Cook, A / Coombes, M / Coquereau, S / Corti, G / Couturier, B / Cowan, G A / Craik, D C / Cunliffe, S / Currie, R / D'Ambrosio, C / David, P / David, P N Y / Davis, A / De Bonis, I / De Bruyn, K / De Capua, S / De Cian, M / De Miranda, J M / De Paula, L / De Silva, W / De Simone, P / Decamp, D / Deckenhoff, M / Del Buono, L / Déléage, N / Derkach, D / Deschamps, O / Dettori, F / Di Canto, A / Dijkstra, H / Dogaru, M / Donleavy, S / Dordei, F / Dosil Suárez, A / Dossett, D / Dovbnya, A / Dupertuis, F / Durante, P / Dzhelyadin, R / Dziurda, A / Dzyuba, A / Easo, S / Egede, U / Egorychev, V / Eidelman, S / van Eijk, D / Eisenhardt, S / Eitschberger, U / Ekelhof, R / Eklund, L / El Rifai, I / Elsasser, Ch / Falabella, A / Färber, C / Farinelli, C / Farry, S / Ferguson, D / Fernandez Albor, V / Ferreira Rodrigues, F / Ferro-Luzzi, M / Filippov, S / Fiore, M / Fitzpatrick, C / Fontana, M / Fontanelli, F / Forty, R / Francisco, O / Frank, M / Frei, C / Frosini, M / Furfaro, E / Gallas Torreira, A / Galli, D / Gandelman, M / Gandini, P / Gao, Y / Garofoli, J / Garosi, P / Garra Tico, J / Garrido, L / Gaspar, C / Gauld, R / Gersabeck, E / Gersabeck, M / Gershon, T / Ghez, Ph / Gibson, V / Giubega, L / Gligorov, V V / Göbel, C / Golubkov, D / Golutvin, A / Gomes, A / Gorbounov, P / Gordon, H / Grabalosa Gándara, M / Graciani Diaz, R / Granado Cardoso, L A / Graugés, E / Graziani, G / Grecu, A / Greening, E / Gregson, S / Griffith, P / Grünberg, O / Gui, B / Gushchin, E / Guz, Yu / Gys, T / Hadjivasiliou, C / Haefeli, G / Haen, C / Haines, S C / Hall, S / Hamilton, B / Hampson, T / Hansmann-Menzemer, S / Harnew, N / Harnew, S T / Harrison, J / Hartmann, T / He, J / Head, T / Heijne, V / Hennessy, K / Henrard, P / Hernando Morata, J A / van Herwijnen, E / Heß, M / Hicheur, A / Hicks, E / Hill, D / Hoballah, M / Hombach, C / Hulsbergen, W / Hunt, P / Huse, T / Hussain, N / Hutchcroft, D / Hynds, D / Iakovenko, V / Idzik, M / Ilten, P / Jacobsson, R / Jaeger, A / Jans, E / Jaton, P / Jawahery, A / Jing, F / John, M / Johnson, D / Jones, C R / Joram, C / Jost, B / Kaballo, M / Kandybei, S / Kanso, W / Karacson, M / Karbach, T M / Kenyon, I R / Ketel, T / Khanji, B / Kochebina, O / Komarov, I / Koopman, R F / Koppenburg, P / Korolev, M / Kozlinskiy, A / Kravchuk, L / Kreplin, K / Kreps, M / Krocker, G / Krokovny, P / Kruse, F / Kucharczyk, M / Kudryavtsev, V / Kurek, K / Kvaratskheliya, T / La Thi, V N / Lacarrere, D / Lafferty, G / Lai, A / Lambert, D / Lambert, R W / Lanciotti, E / Lanfranchi, G / Langenbruch, C / Latham, T / Lazzeroni, C / Le Gac, R / van Leerdam, J / Lees, J-P / Lefèvre, R / Leflat, A / Lefrançois, J / Leo, S / Leroy, O / Lesiak, T / Leverington, B / Li, Y / Li Gioi, L / Liles, M / Lindner, R / Linn, C / Liu, B / Liu, G / Lohn, S / Longstaff, I / Lopes, J H / Lopez-March, N / Lu, H / Lucchesi, D / Luisier, J / Luo, H / Lupton, O / Machefert, F / Machikhiliyan, I V / Maciuc, F / Maev, O / Malde, S / Manca, G / Mancinelli, G / Maratas, J / Marconi, U / Marino, P / Märki, R / Marks, J / Martellotti, G / Martens, A / Martín Sánchez, A / Martinelli, M / Martinez Santos, D / Martins Tostes, D / Martynov, A / Massafferri, A / Matev, R / Mathe, Z / Matteuzzi, C / Maurice, E / Mazurov, A / McCarthy, J / McNab, A / McNulty, R / McSkelly, B / Meadows, B / Meier, F / Meissner, M / Merk, M / Milanes, D A / Minard, M-N / Molina Rodriguez, J / Monteil, S / Moran, D / Morawski, P / Mordà, A / Morello, M J / Mountain, R / Mous, I / Muheim, F / Müller, K / Muresan, R / Muryn, B / Muster, B / Naik, P / Nakada, T / Nandakumar, R / Nasteva, I / Needham, M / Neubert, S / Neufeld, N / Nguyen, A D / Nguyen, T D / Nguyen-Mau, C / Nicol, M / Niess, V / Niet, R / Nikitin, N / Nikodem, T / Nomerotski, A / Novoselov, A / Oblakowska-Mucha, A / Obraztsov, V / Oggero, S / Ogilvy, S / Okhrimenko, O / Oldeman, R / Orlandea, M / Otalora Goicochea, J M / Owen, P / Oyanguren, A / Pal, B K / Palano, A / Palutan, M / Panman, J / Papanestis, A / Pappagallo, M / Parkes, C / Parkinson, C J / Passaleva, G / Patel, G D / Patel, M / Patrick, G N / Patrignani, C / Pavel-Nicorescu, C / Pazos Alvarez, A / Pearce, A / Pellegrino, A / Penso, G / Pepe Altarelli, M / Perazzini, S / Perez Trigo, E / Pérez-Calero Yzquierdo, A / Perret, P / Perrin-Terrin, M / Pescatore, L / Pesen, E / Pessina, G / Petridis, K / Petrolini, A / Phan, A / Picatoste Olloqui, E / Pietrzyk, B / Pilař, T / Pinci, D / Playfer, S / Plo Casasus, M / Polci, F / Polok, G / Poluektov, A / Polycarpo, E / Popov, A / Popov, D / Popovici, B / Potterat, C / Powell, A / Prisciandaro, J / Pritchard, A / Prouve, C / Pugatch, V / Puig Navarro, A / Punzi, G / Qian, W / Rademacker, J H / Rakotomiaramanana, B / Rangel, M S / Raniuk, I / Rauschmayr, N / Raven, G / Redford, S / Reid, M M / Dos Reis, A C / Ricciardi, S / Richards, A / Rinnert, K / Rives Molina, V / Roa Romero, D A / Robbe, P / Roberts, D A / Rodrigues, A B / Rodrigues, E / Rodriguez Perez, P / Roiser, S / Romanovsky, V / Romero Vidal, A / Rouvinet, J / Ruf, T / Ruffini, F / Ruiz, H / Ruiz Valls, P / Sabatino, G / Saborido Silva, J J / Sagidova, N / Sail, P / Saitta, B / Salustino Guimaraes, V / Sanmartin Sedes, B / Santacesaria, R / Santamarina Rios, C / Santovetti, E / Sapunov, M / Sarti, A / Satriano, C / Satta, A / Savrie, M / Savrina, D / Schiller, M / Schindler, H / Schlupp, M / Schmelling, M / Schmidt, B / Schneider, O / Schopper, A / Schune, M-H / Schwemmer, R / Sciascia, B / Sciubba, A / Seco, M / Semennikov, A / Senderowska, K / Sepp, I / Serra, N / Serrano, J / Seyfert, P / Shapkin, M / Shapoval, I / Shatalov, P / Shcheglov, Y / Shears, T / Shekhtman, L / Shevchenko, O / Shevchenko, V / Shires, A / Silva Coutinho, R / Sirendi, M / Skidmore, N / Skwarnicki, T / Smith, N A / Smith, E / Smith, J / Smith, M / Sokoloff, M D / Soler, F J P / Soomro, F / Souza, D / Souza De Paula, B / Spaan, B / Sparkes, A / Spradlin, P / Stagni, F / Stahl, S / Steinkamp, O / Stevenson, S / Stoica, S / Stone, S / Storaci, B / Straticiuc, M / Straumann, U / Subbiah, V K / Sun, L / Sutcliffe, W / Swientek, S / Syropoulos, V / Szczekowski, M / Szczypka, P / Szilard, D / Szumlak, T / T'jampens, S / Teklishyn, M / Teodorescu, E / Teubert, F / Thomas, C / Thomas, E / van Tilburg, J / Tisserand, V / Tobin, M / Tolk, S / Tonelli, D / Topp-Joergensen, S / Torr, N / Tournefier, E / Tourneur, S / Tran, M T / Tresch, M / Tsaregorodtsev, A / Tsopelas, P / Tuning, N / Ubeda Garcia, M / Ukleja, A / Ustyuzhanin, A / Uwer, U / Vagnoni, V / Valenti, G / Vallier, A / Vazquez Gomez, R / Vazquez Regueiro, P / Vázquez Sierra, C / Vecchi, S / Velthuis, J J / Veltri, M / Veneziano, G / Vesterinen, M / Viaud, B / Vieira, D / Vilasis-Cardona, X / Vollhardt, A / Volyanskyy, D / Voong, D / Vorobyev, A / Vorobyev, V / Voß, C / Voss, H / de Vries, J A / Waldi, R / Wallace, C / Wallace, R / Wandernoth, S / Wang, J / Ward, D R / Watson, N K / Webber, A D / Websdale, D / Whitehead, M / Wicht, J / Wiechczynski, J / Wiedner, D / Wiggers, L / Wilkinson, G / Williams, M P / Williams, M / Wilson, F F / Wimberley, J / Wishahi, J / Wislicki, W / Witek, M / Wotton, S A / Wright, S / Wu, S / Wyllie, K / Xie, Y / Xing, Z / Yang, Z / Yuan, X / Yushchenko, O / Zangoli, M / Zavertyaev, M / Zhang, F / Zhang, L / Zhang, W C / Zhang, Y / Zhelezov, A / Zhokhov, A / Zhong, L / Zvyagin, A

Physical review letters

2013 Volume 111, Issue 18, Page(s) 181801

Abstract: The result of a search for the decay B(c)(+) → B(s)(0) π+ is presented, using the B(s)(0) → D(s ... of 7 TeV, and 2 fb(-1) taken at 8 TeV. The decay B(c)(+) → B(s)(0)π+ is observed with significance ... of cross sections and branching fraction is [σ(B(c)(+))/σ(B(s)(0))] × B(B(c)(+)→ B(s)(0)π+) = [2.37 ± 0.31 ...

Abstract	The result of a search for the decay B(c)(+) → B(s)(0) π+ is presented, using the B(s)(0) → D(s)(-)π+ and B(s)(0) → J/ψ Ø channels. The analysis is based on a data sample of pp collisions collected with the LHCb detector, corresponding to an integrated luminosity of 1 fb(-1) taken at a center-of-mass energy of 7 TeV, and 2 fb(-1) taken at 8 TeV. The decay B(c)(+) → B(s)(0)π+ is observed with significance in excess of 5 standard deviations independently in both decay channels. The measured product of the ratio of cross sections and branching fraction is [σ(B(c)(+))/σ(B(s)(0))] × B(B(c)(+)→ B(s)(0)π+) = [2.37 ± 0.31 (stat)± 0.11 (syst)(-0.13)(+0.17)(τ(B)(c)(+)))] × 10(-3), in the pseudorapidity range 2<η(B)<5, where the first uncertainty is statistical, the second is systematic, and the third is due to the uncertainty on the B(c)(+) lifetime. This is the first observation of a B meson decaying to another B meson via the weak interaction.
Language	English
Publishing date	2013-11-01
Publishing country	United States
Document type	Journal Article
ZDB-ID	208853-8
ISSN	1079-7114 ; 0031-9007
ISSN (online)	1079-7114
ISSN	0031-9007
DOI	10.1103/PhysRevLett.111.181801
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Bonn / Germany

Z 4' 58/153: Show issues

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Re: Pathological and Biochemical Outcomes among African-American and Caucasian Men with Low Risk Prostate Cancer in the SEARCH Database: Implications for Active Surveillance Candidacy: M. S. Leapman, S. J. Freedland, W. J. Aronson, C. J. Kane, M. K. Terris, K. Walker, C. L. Amling, P. R. Carroll and M. R. Cooperberg J Urol 2016;196:1408-1414.

Heilbrun, Lance K / Powell, Isaac J

The Journal of urology

2017 Volume 199, Issue 1, Page(s) 305–306

MeSH term(s)	African Americans ; European Continental Ancestry Group ; Humans ; Male ; Prostatic Neoplasms/epidemiology ; Risk
Language	English
Publishing date	2017-09-27
Publishing country	United States
Document type	Letter ; Comment
ZDB-ID	3176-8
ISSN	1527-3792 ; 0022-5347
ISSN (online)	1527-3792
ISSN	0022-5347
DOI	10.1016/j.juro.2017.08.102
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Ui VI Zs.91: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular ab Jg. 2022: Lesesaal (EG)
Zs.MO 331: Show issues

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Re: African American Race is Not Associated with Risk of Reclassification during Active Surveillance: Results from Canary Prostate Cancer Active Surveillance StudyJ. M. Schenk, L. F. Newcomb, Y. Zheng, A. V. Faino, K. Zhu, Y. A. Nyame, J. D. Brooks, P. R. Carroll, M. R. Cooperberg, A. Dash, C. P. Filson, M. E. Gleave, M. Liss, F. M. Martin, T. M. Morgan, P. S. Nelson, I. M. Thompson, A. A. Wagner and D. W. Lin

Powell, Isaac J / Heilbrun, Lance K / Kittles, Rick A

The Journal of urology

2020 Volume 205, Issue 2, Page(s) 338–339

MeSH term(s)	African Americans ; Diagnostic Tests, Routine ; Humans ; Male ; Prostatic Neoplasms ; Watchful Waiting
Language	English
Publishing date	2020-11-06
Publishing country	United States
Document type	Letter ; Comment
ZDB-ID	3176-8
ISSN	1527-3792 ; 0022-5347
ISSN (online)	1527-3792
ISSN	0022-5347
DOI	10.1097/JU.0000000000001443
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Ui VI Zs.91: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular ab Jg. 2022: Lesesaal (EG)
Zs.MO 331: Show issues

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Re: Early detection of prostate cancer: AUA guideline: H. B. Carter, P. C. Albertsen, M. J. Barry, R. Etzioni, S. J. Freedland, K. L. Greene, L. Holmberg, P. Kantoff, B. R. Konety, M. H. Murad, D. F. Penson and A. L. Zietman J Urol 2013; 190: 419-426.

Moul, Judd W / Walsh, Patrick C / Rendell, Marc S / Lynch, Henry T / Leslie, Stephen W / Kosoko-Lasaki, Omofolasade / Fitzgibbons, William P / Powell, Isaac / D'Amico, Anthony V / Catalona, William J

The Journal of urology

2013 Volume 190, Issue 3, Page(s) 1134–1137

MeSH term(s)	Early Detection of Cancer/standards ; Humans ; Male ; Mass Screening/standards ; Prostatic Neoplasms/diagnosis
Language	English
Publishing date	2013-07-17
Publishing country	United States
Document type	Letter ; Comment
ZDB-ID	3176-8
ISSN	1527-3792 ; 0022-5347
ISSN (online)	1527-3792
ISSN	0022-5347
DOI	10.1016/j.juro.2013.07.002
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Ui VI Zs.91: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular ab Jg. 2022: Lesesaal (EG)
Zs.MO 331: Show issues

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article: Ninth International Medical Congress: Held in Washington, D. C., September 5, 6, 7, 8, 9 and 10, 1887.

Powell, T S

The Southern medical record

2022 Volume 17, Issue 11, Page(s) 478–483

Language	English
Publishing date	2022-08-26
Publishing country	United States
Document type	Journal Article
Database	MEDical Literature Analysis and Retrieval System OnLINE

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Details ▾

Article: Trithiacyclononane as a ligand for potential technetium and rhenium radiopharmaceuticals: synthesis of [M(9S3)(SC2H4SC2H4S)][BF4] (M = 99Tc, Re, 188Re) via C-S bond cleavage.

Mullen, G E / Blower, P J / Price, D J / Powell, A K / Howard, M J / Went, M J

Inorganic chemistry

2000 Volume 39, Issue 18, Page(s) 4093–4098

Abstract: ... BF4]2 (M = Re (3a) or Tc (3b)) results in instantaneous C-S bond cleavage to yield ethene and ... C10H20S6Tc, orthorhombic Pbca, a = 12.233(2) A, b = 14.341(2) A, c = 20.726(3) A, Z = 8. ...

Abstract	Chemical or electrochemical reduction of the 1,4,7-trithiacyclononane (9S3) complexes [MII(9S3)2][BF4]2 (M = Re (3a) or Tc (3b)) results in instantaneous C-S bond cleavage to yield ethene and the stable MIII thiolate complexes [MIII(9S3)L][BF4] (M = Re (4a) or Tc (4b), L = SCH2CH2SCH2CH2S). Compounds 4 have been characterized by 1H NMR spectroscopy, and the pseudo-octahedral geometry of 4b has been confirmed by X-ray crystallography. Upon electrochemical reduction 4a loses ethene, while 4b can be reversibly reduced to [TcII(9S3)L], which is then further reduced to Tc(I) with loss of ethene. Successive ethene loss is observed in the mass spectra of compounds 3 and 4. The radiosynthesis of 4a with 188Re can be comfortably completed within 10 min starting with 188ReO4- from a 188W/188Re generator, with a radiochemical yield in excess of 90%, and thus represents a practical approach to the preparation of stable 188Re (and 99mTc) thioether complex derivatives/conjugates for clinical use. Crystal data: 4b, C10H20S6Tc, orthorhombic Pbca, a = 12.233(2) A, b = 14.341(2) A, c = 20.726(3) A, Z = 8.
MeSH term(s)	Alkanes/chemistry ; Carbon/chemistry ; Crystallography, X-Ray ; Ligands ; Molecular Structure ; Radiopharmaceuticals/chemistry ; Rhenium/chemistry ; Spectrum Analysis ; Sulfur/chemistry ; Sulfur Compounds/chemistry ; Technetium Compounds/chemistry
Chemical Substances	Alkanes ; Ligands ; Radiopharmaceuticals ; Sulfur Compounds ; Technetium Compounds ; trithiacyclononane ; Sulfur (70FD1KFU70) ; Rhenium (7440-15-5) ; Carbon (7440-44-0)
Language	English
Publishing date	2000-09-04
Publishing country	United States
Document type	Journal Article ; Research Support, Non-U.S. Gov't
ZDB-ID	1484438-2
ISSN	1520-510X ; 0020-1669
ISSN (online)	1520-510X
ISSN	0020-1669
DOI	10.1021/ic991240m
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Arterial Atherosclerosis: Vascular Surgery Interventions.

Firnhaber, Jonathon M / Powell, C S

American family physician

2022 Volume 105, Issue 1, Page(s) 65–72

Abstract: ... smoking cessation counseling. The U.S. Preventive Services Task Force recommends one-time screening ...

Abstract	Atherosclerotic vascular disease is a leading cause of death worldwide. Atherosclerotic stenosis of the internal carotid or intracranial arteries causes up to 15% of strokes. Peripheral artery disease affects up to one in five people in the United States who are 60 years and older and nearly one-half of those who are 85 years and older. Renal artery stenosis may affect up to 5% of people with isolated hypertension and up to 40% of people with other atherosclerotic diseases. All patients with atherosclerotic vascular disease should receive a comprehensive program of guideline-directed medical therapy, including structured physical activity and lifestyle modification, an antiplatelet agent, a statin, antihypertensive therapy, and smoking cessation counseling. The U.S. Preventive Services Task Force recommends one-time screening for abdominal aortic aneurysm with ultrasonography in men 65 to 75 years of age who have smoked at least 100 cigarettes, but screening is not recommended for carotid, peripheral, and renal disease. Surgical revascularization decreases adverse outcomes and mortality in selected patients with advanced vascular disease. Endovascular repair has become more common for patients younger than 70 years because of decreased short-term mortality. Carotid revascularization with carotid endarterectomy or carotid artery stenting is recommended for symptomatic patients with greater than 50% internal carotid artery stenosis. Carotid artery stenting is preferred in patients with multiple comorbidities, tracheostomy, or previous neck radiation or dissection. In patients older than 70 years, carotid endarterectomy is associated with a lower risk of periprocedural stroke or death than carotid artery stenting. Revascularization is a reasonable treatment option for patients with lifestyle-limiting claudication and an inadequate response to guideline-directed therapies. Revascularization is indicated for patients with critical limb ischemia and is emergently indicated for acute limb ischemia. Renal artery revascularization offers no proven clinical benefit when added to optimal medical therapy.
MeSH term(s)	Aged ; Aged, 80 and over ; Antihypertensive Agents/therapeutic use ; Atherosclerosis/diagnosis ; Atherosclerosis/drug therapy ; Atherosclerosis/epidemiology ; Atherosclerosis/surgery ; Carotid Stenosis/surgery ; Endarterectomy, Carotid/methods ; Exercise ; Female ; Humans ; Hydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use ; Male ; Middle Aged ; Peripheral Arterial Disease/drug therapy ; Peripheral Arterial Disease/surgery ; Platelet Aggregation Inhibitors/therapeutic use ; Risk Factors ; Smoking Cessation/methods ; Stroke/epidemiology ; Ultrasonography/methods ; United States ; Vascular Surgical Procedures/methods
Chemical Substances	Antihypertensive Agents ; Hydroxymethylglutaryl-CoA Reductase Inhibitors ; Platelet Aggregation Inhibitors
Language	English
Publishing date	2022-01-14
Publishing country	United States
Document type	Journal Article
ZDB-ID	412694-4
ISSN	1532-0650 ; 0002-838X ; 0572-3612
ISSN (online)	1532-0650
ISSN	0002-838X ; 0572-3612
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.B 848: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: A case series evaluating patient perceptions after switching from nusinersen to risdiplam for spinal muscular atrophy.

Powell, Jeffrey C / Meiling, James B / Cartwright, Michael S

Muscle & nerve

2023 Volume 69, Issue 2, Page(s) 179–184

Abstract: ... by the U.S. Food and Drug Administration (FDA) for spinal muscular atrophy (SMA). With the later ...

Abstract	Introduction/aims: In 2016, nusinersen became the first disease-modifying medication approved by the U.S. Food and Drug Administration (FDA) for spinal muscular atrophy (SMA). With the later availability of risdiplam in 2020, individuals now have the option of switching from nusinersen to risdiplam. Limited published data exist to inform this decision. This study aims to evaluate the perceptions and experiences of adult participants and parents of minor participants who previously received nusinersen and switched to risdiplam for the treatment of SMA. Methods: Institutional Review Board (IRB) approval was obtained from the Wake Forest IRB prior to the initiation of this study. A cross-sectional, observational study, with qualitative and quantitative data gathered via questionnaire and medical record review, was performed. Inclusion criteria included (1) prior diagnosis of SMA, (2) previous treatment with nusinersen, and (3) change to treatment with risdiplam. No participants were excluded based on age. Results: Fourteen participants-eight adults and six children-were enrolled in the study. Respondents noted improvements in physical function with each medication. Overall, respondents reported worse satisfaction with the method of delivery of the intrathecally delivered nusinersen compared to the orally-delivered risdiplam, but no respondent reported negative overall satisfaction with either medication. A majority (78.6%) of respondents reported that switching from nusinersen to risdiplam was the correct decision. Discussion: These results suggest that most patients are satisfied when switching from nusinersen to risdiplam, with the method of delivery being a primary factor.
MeSH term(s)	Adult ; Child ; Humans ; Azo Compounds ; Cross-Sectional Studies ; Muscular Atrophy, Spinal/drug therapy ; Oligonucleotides/therapeutic use ; Pyrimidines ; Spinal Muscular Atrophies of Childhood/drug therapy
Chemical Substances	Azo Compounds ; nusinersen (5Z9SP3X666) ; Oligonucleotides ; Pyrimidines ; Risdiplam (76RS4S2ET1)
Language	English
Publishing date	2023-12-01
Publishing country	United States
Document type	Observational Study ; Journal Article
ZDB-ID	438353-9
ISSN	1097-4598 ; 0148-639X
ISSN (online)	1097-4598
ISSN	0148-639X
DOI	10.1002/mus.28015
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 1449: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (1.OG) ab Jg. 2022: Lesesaal (EG)
Zs.MO 551: Show issues

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Whole Blood Procoagulant Platelet Flow Cytometry Protocol for Heparin-Induced Thrombocytopenia (HIT) and Vaccine-Induced Immune Thrombotic Thrombocytopenia (VITT) Testing.

Lee, Christine S M / Powell, Matthew C / Chen, Vivien M

Methods in molecular biology (Clifton, N.J.)

2023 Volume 2663, Page(s) 441–461

Abstract: ... the ChAdOx1 nCoV-19 (Vaxzevria, AstraZeneca) and Ad26.COV2.S (Janssen, Johnson & Johnson) vaccines against ...

Abstract	Heparin-induced thrombocytopenia (HIT) is a well-characterized, iatrogenic complication of heparin anticoagulation with significant morbidity. In contrast, vaccine-induced immune thrombotic thrombocytopenia (VITT) is a recently recognized severe prothrombotic complication of adenoviral vaccines, including the ChAdOx1 nCoV-19 (Vaxzevria, AstraZeneca) and Ad26.COV2.S (Janssen, Johnson & Johnson) vaccines against COVID-19. The diagnosis of HIT and VITT involve laboratory testing for antiplatelet antibodies by immunoassays followed by confirmation by functional assays to detect platelet-activating antibodies. Functional assays are critical to detect pathological antibodies due to the varying sensitivity and specificity of immunoassays. This chapter presents a protocol for a novel whole blood flow cytometry-based assay to detect procoagulant platelets in healthy donor blood in response to plasma from patients suspected of HIT or VITT. A method to identify suitable healthy donors for HIT and VITT testing is also described.
MeSH term(s)	Humans ; Blood Platelets ; Ad26COVS1 ; COVID-19 Vaccines/adverse effects ; ChAdOx1 nCoV-19 ; Flow Cytometry ; COVID-19 ; Thrombocytopenia/chemically induced ; Thrombocytopenia/diagnosis ; Thrombosis ; Antibodies ; Vaccines ; Platelet Factor 4
Chemical Substances	Ad26COVS1 (JT2NS6183B) ; COVID-19 Vaccines ; ChAdOx1 nCoV-19 (B5S3K2V0G8) ; Antibodies ; Vaccines ; Platelet Factor 4 (37270-94-3)
Language	English
Publishing date	2023-05-18
Publishing country	United States
Document type	Journal Article ; Research Support, Non-U.S. Gov't
ISSN	1940-6029
ISSN (online)	1940-6029
DOI	10.1007/978-1-0716-3175-1_29
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

Order via subito

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Details ▾
- Full text online
- Order with fees

Article ; Online: Implementing Genomic Testing for Lung Cancer Into Routine Clinical Practice - The Welsh Experience.

Cox, S / Powell, C / Morgan, S

Clinical oncology (Royal College of Radiologists (Great Britain))

2022 Volume 34, Issue 11, Page(s) 716–723

Abstract: Aims: Over the last decade there has been a rapid expansion of clinically actionable driver mutations in non-small cell lung cancer (NSCLC), with an unprecedented number of corresponding targeted therapies approved and funded for use in the clinic. Here ...

Abstract	Aims: Over the last decade there has been a rapid expansion of clinically actionable driver mutations in non-small cell lung cancer (NSCLC), with an unprecedented number of corresponding targeted therapies approved and funded for use in the clinic. Here we summarise the approach taken in Wales to embed a NSCLC biomarker testing pathway within the National Optimal Pathway for Lung Cancer. Materials and methods: The Welsh Thoracic Oncology Group established a working group tasked with progressing the standardisation of genomic testing. In July 2021, the 10 lung cancer multidisciplinary teams (MDTs) were invited to take part in a national survey of current biomarker testing practices and a retrospective audit of the next generation sequencing (NGS) pathway in Wales was conducted. Results: Seventy per cent of MDTs completed the survey, which confirmed variability in the approach to testing with respect to timing of requests, patient selection and testing technologies used. Only 43% reported having pathology-initiated reflex testing, but 87% had adopted DNA and RNA NGS testing as their standard-of-care genomic testing strategy. Data from 53 patients with stage III-IV NSCLC with genomic testing requested between October 2020 and May 2021 were analysed in the NGS pathway audit. Forty (75.5%) patients had both DNA and RNA NGS requested, with a median turnaround time from biopsy to results of 26 days (range 19-37 days) and 25 days (range 16-38 days), respectively. The geographical location of MDT did not influence turnaround times and MDTs with reflex testing had shorter biopsy-to-result times. DNA NGS testing was successful in 51 (96.2%) patients; in those who had RNA NGS, testing was successful in 30 (75%) patients. Conclusion: Significant progress has been made within Wales to implement a national biomarker testing pathway, with reflex testing becoming standard of care. However, challenges remain in optimising the quantity and quality of tissue available for testing, together with a need to reduce turnaround times. This will need to be addressed to ensure all eligible patients are tested at the right time in the diagnostic pathway to facilitate optimal treatment strategies and ultimately improve outcomes.
MeSH term(s)	Carcinoma, Non-Small-Cell Lung/diagnosis ; Carcinoma, Non-Small-Cell Lung/genetics ; Carcinoma, Non-Small-Cell Lung/pathology ; Genetic Testing ; High-Throughput Nucleotide Sequencing/methods ; Humans ; Lung Neoplasms/diagnosis ; Lung Neoplasms/drug therapy ; Lung Neoplasms/genetics ; Mutation ; RNA/therapeutic use ; Retrospective Studies
Chemical Substances	RNA (63231-63-0)
Language	English
Publishing date	2022-09-08
Publishing country	England
Document type	Journal Article
ZDB-ID	1036844-9
ISSN	1433-2981 ; 0936-6555
ISSN (online)	1433-2981
ISSN	0936-6555
DOI	10.1016/j.clon.2022.08.025
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 2774: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

To top

More links

Kategorien

In stock of ZB MED Bonn / Germany

Order via subito

Inter-library loan at ZB MED

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Inter-library loan at ZB MED

More links

Kategorien

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

Order via subito

Inter-library loan at ZB MED

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito